Zionexa is pleased to join GE Healthcare to further develop molecular imaging agents in oncology, all aimed at enabling more precise diagnosis, improved treatment decision-making and ultimately better clinical outcomes for patients.
Our mission has always been to help physicians personalize treatment to improve patients’ pathway and quality of life. We are delighted to be joining an organization rooted in precision health.
Kevin O’Neill, President and CEO of GE Healthcare Pharmaceutical Diagnostics, said: “Like GE Healthcare, Zionexa’s products are aimed at enabling more precise diagnosis, improved treatment decision-making and ultimately better clinical outcomes for patients. This acquisition further demonstrates our commitment to enabling precision health and providing innovations that support oncologists, nuclear medicine specialists and other physicians throughout a cancer patient’s journey, from initial screening and diagnosis to informing therapy selection and monitoring the effectiveness of treatment.”
Olivier Carli, President of Denos, the majority owner of Zionexa, said: “We expect GE Healthcare Pharmaceutical Diagnostics’ acquisition to allow Zionexa to accelerate the development of its promising R&D pipeline as well as its commercial footprint, while providing Zionexa’s team with access to global and complementary expertise.”